Haematological Evaluation of Weekly Therapy with Topotecan for the Treatment of Recurrent Ovarian Cancer Resistant to Platinum-Based Therapy

Publisher： Karger

E-ISSN： 1423-0232|73|3-4|177-184

ISSN： 0030-2414

Source： Oncology, Vol.73, Iss.3-4, 2008-04, pp. : 177-184

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Topotecan and Gemcitabine in Platinum/Paclitaxel-Resistant Ovarian Cancer

By  

Oncology, Vol. 60, Iss. 1, 2000-12 ,pp. : 19-23

Karger

Access to resources Recommend Favorite

Topotecan (Hycamtin) in the Therapy of Recurrent Ovarian Carcinoma

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 2-5

Karger

Access to resources Recommend Favorite

Radiation Therapy for Chemotherapy-Resistant Recurrent Epithelial Ovarian Cancer

By  

Oncology, Vol. 86, Iss. 4, 2014-05 ,pp. : 232-238

Karger

Access to resources Recommend Favorite

Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

By  

Oncology, Vol. 71, Iss. 5-6, 2007-09 ,pp. : 320-326

Karger

Access to resources Recommend Favorite

Dose Finding Study for Combination Treatment with Topotecan and Gemcitabine of Patients with Recurrent Ovarian Cancer after Failure of First-Line Chemotherapy with Paclitaxel and Platinum

By  

Oncology Research and Treatment, Vol. 27, Iss. 1, 2004-03 ,pp. : 58-64

Karger

Access to resources Recommend Favorite